Other Vaccines - Norway

Norway

Highlights

The projected revenue for the Other Vaccines market in Norway is estimated to reach US$155.30m by 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 9.45%, leading to a market volume of US$243.80m by 2029.
In comparison to other countries, United States is anticipated to generate the highest revenue of US$24.73bn in 2024.
Norway is experiencing a growing demand for other vaccines, driven by a strong commitment to public health and a proactive approach to disease prevention.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in Norway has been experiencing steady growth in recent years.

Customer preferences: Norwegian consumers have been increasingly interested in preventative healthcare measures, including vaccinations. This trend is in line with global patterns, as individuals become more aware of the importance of maintaining their health and preventing illnesses. Additionally, there has been a growing interest in alternative and complementary medicine in Norway, which has led to an increased demand for non-traditional vaccines.

Trends in the market: One of the most significant trends in the Other Vaccines market in Norway is the rising demand for vaccines that protect against infectious diseases. This trend is driven by a number of factors, including increased travel to areas with high disease prevalence, a growing awareness of the risks associated with infectious diseases, and a general trend towards preventative healthcare. Additionally, there has been a growing interest in non-traditional vaccines, such as those derived from plants or other natural sources.

Local special circumstances: Norway has a well-developed healthcare system that provides universal coverage to all citizens. This has helped to facilitate the widespread adoption of preventative healthcare measures, including vaccinations. Additionally, the Norwegian government has implemented a number of policies aimed at promoting public health and preventing the spread of infectious diseases. These policies include mandatory vaccinations for certain groups, such as healthcare workers and children attending school.

Underlying macroeconomic factors: The Norwegian economy has been growing steadily in recent years, which has helped to support the growth of the Other Vaccines market. Additionally, the country has a high level of disposable income, which has enabled consumers to invest in preventative healthcare measures. Finally, the Norwegian government has made significant investments in the healthcare sector, which has helped to facilitate the development and distribution of new vaccines.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.